Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 74

1.

Facilitators and barriers to the successful implementation of pediatric antibacterial drug trials: Findings from CTTI's survey of investigators.

Corneli A, Wheeler C, Bradley J, Gamel B, Nambiar S, Noel GJ, Lin L, Roberts JN, Benjamin DK Jr.

Contemp Clin Trials Commun. 2018 Jan 31;9:115-120. doi: 10.1016/j.conctc.2018.01.003. eCollection 2018 Mar.

2.

Perceived barriers to pediatrician and family practitioner participation in pediatric clinical trials: Findings from the Clinical Trials Transformation Initiative.

Greenberg RG, Corneli A, Bradley J, Farley J, Jafri HS, Lin L, Nambiar S, Noel GJ, Wheeler C, Tiernan R, Smith PB, Roberts J, Benjamin DK Jr.

Contemp Clin Trials Commun. 2017 Nov 26;9:7-12. doi: 10.1016/j.conctc.2017.11.006. eCollection 2018 Mar.

3.

Advancing Pediatric Antibacterial Drug Development: A Critical Need to Reinvent our Approach.

Noel GJ, Nambiar S, Bradley J; Clinical Trials Transformation Initiative’s Pediatric Antibiotic Drug Development Program.

J Pediatric Infect Dis Soc. 2019 Mar 28;8(1):60-62. doi: 10.1093/jpids/piy001. Review.

4.

Improving Conduct and Feasibility of Clinical Trials to Evaluate Antibacterial Drugs to Treat Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial Pneumonia: Recommendations of the Clinical Trials Transformation Initiative Antibacterial Drug Development Project Team.

Knirsch C, Alemayehu D, Botgros R, Comic-Savic S, Friedland D, Holland TL, Merchant K, Noel GJ, Pelfrene E, Reith C, Santiago J, Tiernan R, Tenearts P, Goldsack JC, Fowler VG Jr.

Clin Infect Dis. 2016 Aug 15;63 Suppl 2:S29-36. doi: 10.1093/cid/ciw258.

PMID:
27481950
5.

Assessment of musculoskeletal toxicity 5 years after therapy with levofloxacin.

Bradley JS, Kauffman RE, Balis DA, Duffy CM, Gerbino PG, Maldonado SD, Noel GJ.

Pediatrics. 2014 Jul;134(1):e146-53. doi: 10.1542/peds.2013-3636. Epub 2014 Jun 2.

PMID:
24918220
6.

Children's medicines in Tanzania: a national survey of administration practices and preferences.

Adams LV, Craig SR, Mmbaga EJ, Naburi H, Lahey T, Nutt CT, Kisenge R, Noel GJ, Spielberg SP.

PLoS One. 2013;8(3):e58303. doi: 10.1371/journal.pone.0058303. Epub 2013 Mar 6.

7.

Improving drug formulations for neonates: making a big difference in our smallest patients.

Noel GJ, Van Den Anker JN, Lombardi D, Ward R.

J Pediatr. 2012 Nov;161(5):947-9. doi: 10.1016/j.jpeds.2012.07.016. No abstract available.

PMID:
23095694
8.

A randomized, evaluator-blind, phase 2 study comparing the safety and efficacy of omadacycline to those of linezolid for treatment of complicated skin and skin structure infections.

Noel GJ, Draper MP, Hait H, Tanaka SK, Arbeit RD.

Antimicrob Agents Chemother. 2012 Nov;56(11):5650-4. doi: 10.1128/AAC.00948-12. Epub 2012 Aug 20.

9.

A randomised, double-blind trial comparing ceftobiprole medocaril with ceftriaxone with or without linezolid for the treatment of patients with community-acquired pneumonia requiring hospitalisation.

Nicholson SC, Welte T, File TM Jr, Strauss RS, Michiels B, Kaul P, Balis D, Arbit D, Amsler K, Noel GJ.

Int J Antimicrob Agents. 2012 Mar;39(3):240-6. doi: 10.1016/j.ijantimicag.2011.11.005. Epub 2012 Jan 9.

PMID:
22230331
10.

Mice treated with a benzodiazepine had an improved survival rate following Pseudomonas aeruginosa infection.

Dugan AL, Gregerson KA, Neely A, Gardner J, Noel GJ, Babcock GF, Horseman ND.

J Burn Care Res. 2010 Jan-Feb;31(1):1-12. doi: 10.1097/BCR.0b013e3181cb8e82.

PMID:
20061831
11.

Pharmacometrics-based dose selection of levofloxacin as a treatment for postexposure inhalational anthrax in children.

Li F, Nandy P, Chien S, Noel GJ, Tornoe CW.

Antimicrob Agents Chemother. 2010 Jan;54(1):375-9. doi: 10.1128/AAC.00667-09. Epub 2009 Oct 26.

12.

Pharmacodynamic profiling of ceftobiprole for treatment of complicated skin and skin structure infections.

Kimko H, Xu X, Nandy P, Samtani MN, Strauss RS, Bagchi P, Noel GJ.

Antimicrob Agents Chemother. 2009 Aug;53(8):3371-4. doi: 10.1128/AAC.01653-08. Epub 2009 Jun 15.

13.

Identifying exposure targets for treatment of staphylococcal pneumonia with ceftobiprole.

Rodvold KA, Nicolau DP, Lodise TP, Khashab M, Noel GJ, Kahn JB, Gotfried M, Murray SA, Nicholson S, Laohavaleeson S, Tessier PR, Drusano GL.

Antimicrob Agents Chemother. 2009 Aug;53(8):3294-301. doi: 10.1128/AAC.00144-09. Epub 2009 May 18.

14.

Population pharmacokinetic analysis of ceftobiprole for treatment of complicated skin and skin structure infections.

Kimko H, Murthy B, Xu X, Nandy P, Strauss R, Noel GJ.

Antimicrob Agents Chemother. 2009 Mar;53(3):1228-30. doi: 10.1128/AAC.00632-08. Epub 2008 Dec 15.

15.

Differential immunological phenotypes are exhibited after scald and flame burns.

Tschöp J, Martignoni A, Reid MD, Adediran SG, Gardner J, Noel GJ, Ogle CK, Neely AN, Caldwell CC.

Shock. 2009 Feb;31(2):157-63. doi: 10.1097/SHK.0b013e31817fbf4d.

16.

A randomized comparative study of levofloxacin versus amoxicillin/clavulanate for treatment of infants and young children with recurrent or persistent acute otitis media.

Noel GJ, Blumer JL, Pichichero ME, Hedrick JA, Schwartz RH, Balis DA, Melkote R, Bagchi P, Arguedas A.

Pediatr Infect Dis J. 2008 Jun;27(6):483-9. doi: 10.1097/INF.0b013e318168d2cb.

PMID:
18449063
17.

Stress and prolactin effects on bone marrow myeloid cells, serum chemokine and serum glucocorticoid levels in mice.

Dugan AL, Schwemberger S, Noel GJ, Babcock GF, Ogle CK, Buckley DJ, Horseman ND, Gregerson KA.

Neuroimmunomodulation. 2007;14(6):287-96. doi: 10.1159/000117810. Epub 2008 Feb 21.

PMID:
18287810
18.
19.

Characterization and dynamics of middle ear fluid and nasopharyngeal isolates of Streptococcus pneumoniae from 12 children treated with levofloxacin.

Davies TA, Leibovitz E, Noel GJ, McNeeley DF, Bush K, Dagan R.

Antimicrob Agents Chemother. 2008 Jan;52(1):378-81. Epub 2007 Nov 12.

20.

Results of a double-blind, randomized trial of ceftobiprole treatment of complicated skin and skin structure infections caused by gram-positive bacteria.

Noel GJ, Strauss RS, Amsler K, Heep M, Pypstra R, Solomkin JS.

Antimicrob Agents Chemother. 2008 Jan;52(1):37-44. Epub 2007 Oct 22.

21.

Comparative safety profile of levofloxacin in 2523 children with a focus on four specific musculoskeletal disorders.

Noel GJ, Bradley JS, Kauffman RE, Duffy CM, Gerbino PG, Arguedas A, Bagchi P, Balis DA, Blumer JL.

Pediatr Infect Dis J. 2007 Oct;26(10):879-91.

PMID:
17901792
22.

Comparative study of levofloxacin in the treatment of children with community-acquired pneumonia.

Bradley JS, Arguedas A, Blumer JL, Sáez-Llorens X, Melkote R, Noel GJ.

Pediatr Infect Dis J. 2007 Oct;26(10):868-78.

PMID:
17901791
23.

Clinical profile of ceftobiprole, a novel beta-lactam antibiotic.

Noel GJ.

Clin Microbiol Infect. 2007 Jun;13 Suppl 2:25-9. Review.

24.

Probability of target attainment for ceftobiprole as derived from a population pharmacokinetic analysis of 150 subjects.

Lodise TP Jr, Pypstra R, Kahn JB, Murthy BP, Kimko HC, Bush K, Noel GJ, Drusano GL.

Antimicrob Agents Chemother. 2007 Jul;51(7):2378-87. Epub 2007 Mar 26.

25.

Anti-MRSA beta-lactams in development, with a focus on ceftobiprole: the first anti-MRSA beta-lactam to demonstrate clinical efficacy.

Bush K, Heep M, Macielag MJ, Noel GJ.

Expert Opin Investig Drugs. 2007 Apr;16(4):419-29. Review.

PMID:
17371191
26.

Psychogenic stress prior to burn injury has differential effects on bone marrow and cytokine responses.

Dugan AL, Schwemberger S, Noel GJ, Babcock G, Ogle CK, Horseman ND.

Exp Biol Med (Maywood). 2007 Feb;232(2):253-61.

PMID:
17259333
27.

An open-label, double tympanocentesis study of levofloxacin therapy in children with, or at high risk for, recurrent or persistent acute otitis media.

Arguedas A, Dagan R, Pichichero M, Leibovitz E, Blumer J, McNeeley DF, Melkote R, Noel GJ.

Pediatr Infect Dis J. 2006 Dec;25(12):1102-9.

PMID:
17133154
28.

Achilles tendon rupture and its association with fluoroquinolone antibiotics and other potential risk factors in a managed care population.

Seeger JD, West WA, Fife D, Noel GJ, Johnson LN, Walker AM.

Pharmacoepidemiol Drug Saf. 2006 Nov;15(11):784-92.

PMID:
16456878
29.

Levofloxacin pharmacokinetics in children.

Chien S, Wells TG, Blumer JL, Kearns GL, Bradley JS, Bocchini JA Jr, Natarajan J, Maldonado S, Noel GJ.

J Clin Pharmacol. 2005 Feb;45(2):153-60.

PMID:
15647407
30.

Measuring the effects of supratherapeutic doses of levofloxacin on healthy volunteers using four methods of QT correction and periodic and continuous ECG recordings.

Noel GJ, Goodman DB, Chien S, Solanki B, Padmanabhan M, Natarajan J.

J Clin Pharmacol. 2004 May;44(5):464-73.

PMID:
15102866
31.
32.

Effects of three fluoroquinolones on QT interval in healthy adults after single doses.

Noel GJ, Natarajan J, Chien S, Hunt TL, Goodman DB, Abels R.

Clin Pharmacol Ther. 2003 Apr;73(4):292-303.

PMID:
12709719
33.

Tendon or joint disorders in children after treatment with fluoroquinolones or azithromycin.

Yee CL, Duffy C, Gerbino PG, Stryker S, Noel GJ.

Pediatr Infect Dis J. 2002 Jun;21(6):525-9.

PMID:
12182376
34.

Effect of ciprofloxacin on lethal and sublethal challenge with endotoxin and on early cytokine responses in a murine in vivo model.

Purswani MU, Eckert SJ, Arora HK, Noel GJ.

J Antimicrob Chemother. 2002 Jul;50(1):51-8.

PMID:
12096006
35.

Cytokine modulation with immune gamma-globulin in peripheral blood of normal children and its implications in Kawasaki disease treatment.

Gupta M, Noel GJ, Schaefer M, Friedman D, Bussel J, Johann-Liang R.

J Clin Immunol. 2001 May;21(3):193-9.

PMID:
11403226
36.
37.

Antimicrobial-resistant enterococcal isolates from fluoroquinolone-naive children.

McNeeley DF, Eckert SJ, Noel GJ.

Pediatr Infect Dis J. 2000 Jul;19(7):675-6. No abstract available.

PMID:
10917238
38.

Energy balance, viral burden, insulin-like growth factor-1, interleukin-6 and growth impairment in children infected with human immunodeficiency virus.

Johann-Liang R, O'Neill L, Cervia J, Haller I, Giunta Y, Licholai T, Noel GJ.

AIDS. 2000 Apr 14;14(6):683-90.

PMID:
10807191
39.

Genotypic characterization of human immunodeficiency virus type 1 isolated from vertically infected children with antiretroviral therapy experience.

Johann-Liang R, Lee SE, Fernandez A, Cervia J, Noel GJ.

Pediatr Infect Dis J. 2000 Apr;19(4):363-4. No abstract available.

PMID:
10783035
40.

Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia.

Noel GJ.

J Pediatr. 1999 Sep;135(3):399. No abstract available.

PMID:
10523149
41.
42.

Abnormal regulation of interferon-gamma, interleukin-12, and tumor necrosis factor-alpha in human interferon-gamma receptor 1 deficiency.

Holland SM, Dorman SE, Kwon A, Pitha-Rowe IF, Frucht DM, Gerstberger SM, Noel GJ, Vesterhus P, Brown MR, Fleisher TA.

J Infect Dis. 1998 Oct;178(4):1095-104.

PMID:
9806040
43.

Reversal of proinflammatory responses by ligating the macrophage Fcgamma receptor type I.

Sutterwala FS, Noel GJ, Salgame P, Mosser DM.

J Exp Med. 1998 Jul 6;188(1):217-22.

44.

An investigation of vancomycin-resistant Enterococcus faecium within the pediatric service of a large urban medical center.

McNeeley DF, Brown AE, Noel GJ, Chung M, De Lencastre H.

Pediatr Infect Dis J. 1998 Mar;17(3):184-8.

PMID:
9535243
45.

Characteristics of human immunodeficiency virus-infected children at the time of death: an experience in the 1990s.

Johann-Liang R, Cervia JS, Noel GJ.

Pediatr Infect Dis J. 1997 Dec;16(12):1145-50.

PMID:
9427460
46.

Endogenous interleukin-2 serum levels in children infected with human immunodeficiency virus.

Johann-Liang R, Cervia J, Noel GJ.

Clin Infect Dis. 1997 Nov;25(5):1233-6.

PMID:
9402387
47.

Selective suppression of interleukin-12 induction after macrophage receptor ligation.

Sutterwala FS, Noel GJ, Clynes R, Mosser DM.

J Exp Med. 1997 Jun 2;185(11):1977-85.

48.
49.

Neonatal enterococcal bacteremia: an increasingly frequent event with potentially untreatable pathogens.

McNeeley DF, Saint-Louis F, Noel GJ.

Pediatr Infect Dis J. 1996 Sep;15(9):800-5.

PMID:
8878225
50.

Successful combination vancomycin and rifampin therapy in a newborn with community-acquired Flavobacterium meningosepticum neonatal meningitis.

Tizer KB, Cervia JS, Dunn AM, Stavola JJ, Noel GJ.

Pediatr Infect Dis J. 1995 Oct;14(10):916-7. No abstract available.

PMID:
8584328

Supplemental Content

Support Center